The Analyst Verdict: TG Therapeutics In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on TG Therapeutics (NASDAQ:TGTX), with most being bullish. The average 12-month price target has increased to $40.4. The company has shown strong financial performance with significant revenue growth and high net margins, but faces challenges with debt management.
October 29, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a predominantly bullish outlook on TG Therapeutics, with an increased average price target of $40.4. The company shows strong financial performance but faces challenges with debt management.
The majority of analysts have a bullish outlook on TGTX, with a significant increase in the average price target. The company's strong financial performance, including high revenue growth and net margins, supports a positive short-term impact. However, the high debt-to-equity ratio poses a risk, which slightly tempers the overall positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100